Email this article Analysis of ineffective antiviral therapy with pegylated interferon and ribavirin in a patient with chronic hepatitis C infected with HCV genotype 2
- Authors: Znoyko OO1, Dudina KR1, Kozina AN1, Kalininа OV2, Yushchuk ND1
-
Affiliations:
- «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России
- Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера
- Issue: Vol 88, No 5 (2016)
- Pages: 84-85
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32001
- ID: 32001
Cite item
Full Text
Abstract
The paper describes a case of ineffective dual antiviral therapy (pegylated interferon and ribavirin) in a patient with chronic hepatitis C infected with hepatitis C virus (HCV) genotype 2 according to the data from the use of a commercial test system. Analysis of the predictors of failure of antiviral therapy (AVT) (the HCV recombinant variant RF2k/1b, a high viral load before the start of therapy, an unfavorable IL-28B genotype, a high body mass index, and a need for a lower ribavirin dose after 12 weeks of AVT because of adverse reactions for less than 4 weeks) in this patient has shown that no virological response is mainly associated with the presence of the HCV recombinant variant, the treatment effectiveness of which is comparable with that in HCV genotype 1 and obesity. In this connection, when HCV genotype 2 is identified, sequencing the NS5B region of the HCV genome is additionally recommended to rule out the virus recombinant strain and, if it is detected, highly effective interferon-free therapy with direct-acting antivirals is indicated.
About the authors
O O Znoyko
«Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России
K R Dudina
«Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России
A N Kozina
«Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России
O V Kalininа
Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. ПастераСанкт-Петербург, Россия
N D Yushchuk
«Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России
References
- Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin. Aliment Pharmacol Ther. 2012;36(2):91-103. doi: 10.1111/j.1365-2036.2012.05131.x.
- Alsiö Å, Rembeck K, Askarieh G, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Haagmans BL, Nasic S, Westin J, Hellstrand K, Norkrans G, Lagging M. Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. PLoS One. 2012;7(5):e37521. doi: 10.1371/journal.pone.0037521.
- Craxì A, Piccinino F, Ciancio A, Iannacone C, Deodato B, Golotta C, Ascione A. Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study. EurJ Gastroenterol Hepatol. 2014;26(4):388-395. doi: 10.1097/MEG.0000000000000039.
